FibroGen Inc
(NAS:FGEN)
$
0.58
0.001 (0.17%)
Market Cap: 58.45 Mil
Enterprise Value: 48.65 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 49/100 FibroGen Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020 / 03:00PM GMT
Release Date Price:
$36.28
(+0.53%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research
Good day, everybody. My name is Jason Gerberry. I cover smid-cap biotech and especially pharmaceutical for Bank of America. I'm pleased to be introducing our next company presenter, FibroGen and new CEO, Enrique Conterno. FibroGen is -- most would know the company for its development of roxadustat for anemia associated with dialysis or renal disease, but the company also has an emerging early to mid-stage pipeline with pamrevlumab for fibrotic disorders.
So Enrique, first off, thanks for joining us at the conference on a virtual basis.
Enrique A. Conterno
FibroGen, Inc. - CEO & Director
No, thank you, Jason. It's a pleasure for me to be here and talk about the progress we're making at FibroGen.
Questions & Answers
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research
Great. I mean, look, you're no longer new to the role, but I imagine that the opportunity with
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot